Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Metabolite Profile of [14C]-APX001 in Healthy Males
NCT04804059Phase 1Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Aug 2018
- Primary completion
- Sep 2018
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fosmanogepix in fungal infection (2 cohorts), sponsored by Basilea Pharmaceutica. Primary endpoints: Mass balance recovery as measured by mass unit equiv/g at 3 weeks and Profiling of metabolites of [14C]-APX001 in plasma and excreta at 3 weeks. Started Aug 2018; status: completed.
02
Drugs
fosmanogepix
03
Conditions
fungal infection
Beyond the preview
Go deeper on NCT04804059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04804059.